To Cite:
El-Mashad
N B E, Abdel Aal
A M, Elewa
A M, Saad Elshaer
M Y. Nosocomial Yeast Infections Among Cancer Patients in Egypt: Species Distribution and Antifungal Susceptibility Profile,
Jundishapur J Microbiol.
Online ahead of Print
; 12(2):e82421.
doi: 10.5812/jjm.82421.
4.
Aydemir Ö, Demiray T, Köroglu M, Aydemir Y, Altindi M. Emerge of non-albicans Candida species; evaluation of Candida species and antifungal susceptibilities according to years. Biomedical Research. 2017;28(6).
5.
Liao Y, Lu X, Yang S, Luo Y, Chen Q, Yang R. Epidemiology and outcome of trichosporon fungemia: A review of 185 reported cases from 1975 to 2014. Open Forum Infect Dis. 2015;2(4):ofv141. doi: 10.1093/ofid/ofv141. [PubMed: 26566536]. [PubMed Central: PMC4630454].
6.
Miglietta F, Letizia Faneschi M, Braione A, Palumbo C, Rizzo A, Lobreglio G, et al. Central venous catheter-related fungemia caused by Rhodotorula glutinis. Med Mycol J. 2015;56(3):E17-9. doi: 10.3314/mmj.56.E17. [PubMed: 26329371].
8.
Singh GK, Capoor MR, Nair D, Bhowmik KT. Spectrum of fungal infection in head and neck cancer patients on chemoradiotherapy. J Egypt Natl Canc Inst. 2017;29(1):33-7. doi: 10.1016/j.jnci.2017.01.006. [PubMed: 28258917].
9.
Patolia S, Kennedy E, Zahir M, Patolia S, Gulati N, Narendra D, et al. Risk factors for candida blood stream infection in medical ICU and role of colonization-A retrospective study. Br J Med Pract. 2013;6(2):a618.
10.
Fisher BT, Robinson PD, Lehrnbecher T, Steinbach WJ, Zaoutis TE, Phillips B, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: A systematic review. J Pediatric Infect Dis Soc. 2018;7(3):191-8. doi: 10.1093/jpids/pix030. [PubMed: 28549148].
11.
Sandhu R, Dahiya S, Sayal P, Budhani D. Increased role of nonalbicans Candida, potential risk factors, and attributable mortality in hospitalized patients. J Health Res Rev. 2017;4(2):78-83. doi: 10.4103/2394-2010.208115.
12.
Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(Pt 1):10-24. doi: 10.1099/jmm.0.045054-0. [PubMed: 23180477].
13.
Zhang L, Zhou S, Pan A, Li J, Liu B. Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis. 2015;33:1-4. doi: 10.1016/j.ijid.2014.12.033. [PubMed: 25541294].
14.
Pahwa N, Kumar R, Nirkhiwale S, Bandi A. Species distribution and drug susceptibility of candida in clinical isolates from a tertiary care centre at Indore. Indian J Med Microbiol. 2014;32(1):44-8. doi: 10.4103/0255-0857.124300. [PubMed: 24399387].
15.
Kumari KS, Raghunath P, Harshavardhan B, Chaudhury A. Distribution of Candida albicans and the non-albicans Candida species in different clinical specimens from South India. Int J Microbiol Res. 2014;5:1-5. doi: 10.5829/idosi.ijmr.2014.5.1.8232.
16.
Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project). Infection. 2013;41(3):645-53. doi: 10.1007/s15010-013-0432-0. [PubMed: 23463186]. [PubMed Central: PMC3671106].
17.
Ding X, Yan D, Sun W, Zeng Z, Su R, Su J. Epidemiology and risk factors for nosocomial non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China. Med Mycol. 2015;53(7):684-90. doi: 10.1093/mmy/myv060. [PubMed: 26229153].
18.
Sharma Y, Chumber SK, Kaur M. Studying the prevalence, species distribution, and detection of in vitro production of phospholipase from candida isolated from cases of invasive candidiasis. J Glob Infect Dis. 2017;9(1):8-11. doi: 10.4103/0974-777X.199995. [PubMed: 28250619]. [PubMed Central: PMC5330047].
19.
Magalhaes YC, Bomfim MR, Melonio LC, Ribeiro PC, Cosme LM, Rhoden CR, et al. Clinical significance of the isolation of Candida species from hospitalized patients. Braz J Microbiol. 2015;46(1):117-23. doi: 10.1590/S1517-838246120120296. [PubMed: 26221096]. [PubMed Central: PMC4512074].
20.
Siqueira RA, Doi AM, de Petrus Crossara PP, Koga PCM, Marques AG, Nunes FG, et al. Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2((R)) and Sensititre YeastOne((R)). Rev Iberoam Micol. 2018;35(2):83-7. doi: 10.1016/j.riam.2017.11.001. [PubMed: 29580699].
21.
Marcos-Zambrano LJ, Puig-Asensio M, Perez-Garcia F, Escribano P, Sanchez-Carrillo C, Zaragoza O, et al. Candida guilliermondii complex is characterized by high antifungal resistance but low mortality in 22 cases of candidemia. Antimicrob Agents Chemother. 2017;61(7). doi: 10.1128/AAC.00099-17. [PubMed: 28438935]. [PubMed Central: PMC5487632].
22.
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366-77. doi: 10.1128/JCM.02117-09. [PubMed: 20164282]. [PubMed Central: PMC2849609].
23.
Czaika V, Nenoff P, Glockner A, Becker K, Fegeler W, Schmalreck AF. Detection of azole susceptibility patterns in clinical yeast strains isolated from 1998 to 2008. New Microbiol. 2014;37(4):465-94. [PubMed: 25387285].
24.
Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61 Suppl 6:S612-7. doi: 10.1093/cid/civ791. [PubMed: 26567278]. [PubMed Central: PMC4643482].
Readers' Comments